journal article·2025-08Open access

An Anisotropic Gold‐Palladium Heterostructured Nanosystem for Synergistically Overcoming Radioresistance and Enhancing Melanoma Radioimmunotherapy

Cheng Chen, Yuqi Huang, Wandong Wang, Minghao Chao, Weiguo Sun, Yinghui Kong, Guan Jiang, Yong Gao, Fenglei Gao

Advanced Science· Volume 12· Issue 31

Abstract

Abstract Radiotherapy (RT) has recently reemerged as a promising approach for melanoma treatment because of its potential to trigger abscopal effects. However, the intrinsic radioresistance of melanoma significantly diminishes RT‐induced DNA damage and the subsequent release of immunostimulatory molecules, thereby impairing systemic antitumor immunity. To overcome these challenges, a multifunctional anisotropic Au‐Pd heterostructured nanosystem (APSMR) is developed that incorporates a plasmonically enhanced Au‐Pd core, with a shell composed of a biodegradable, Mn‐doped targeting peptide. The nanosystem integrates photothermal, radiotherapeutic, and immunomodulatory functions. Under 1064 nm laser irradiation, APSMR generates reactive oxygen species (ROS) via plasmon‐driven catalysis and Mn‐mediated Fenton‐like reactions. Concurrently, mild hyperthermia (HT) promotes oxygenation and disrupts DNA repair pathways, resulting in multi‐directional DNA damage and an increase in immunogenic cell death (ICD). Furthermore, the release of Mn2⁺ ions activates the cGAS–STING pathway, which synergizes with ICD to promote systemic antitumor immunity. Notably, APSMR treatment also upregulates PD‐L1 expression, thereby sensitizing tumors to immune checkpoint blockade. Collectively, APSMR offers a potent and synergistic strategy to amplify RT‐driven tumor vaccination and improve therapeutic responses against metastatic melanoma.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Machine Learning in Materials Science · Gold and Silver Nanoparticles Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Dermatology The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University Jiangsu 223300 P. R. China

Department of Dermatology The Affiliated Suzhou Hospital of Nanjing Medical University Jiangsu 215000 P. R. China

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy Xuzhou Medical University Jiangsu 221004 P. R. China

Department of Dermatology University Medical Center Groningen University of Groningen Groningen 9713 GZ the Netherlands

Department of Dermatology Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu 221002 P. R. China

Department of Oncology The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University Jiangsu 223300 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (48)

Show source-provided references
1. 10.1126/science.aar711210.1126/science.aar7112 ↗
2. 10.1186/s13045-022-01247-x10.1186/s13045-022-01247-x ↗
3. 10.1038/s41568-021-00346-010.1038/s41568-021-00346-0 ↗
4. 10.1038/s41392-023-01674-310.1038/s41392-023-01674-3 ↗
5. 10.1016/j.ctrv.2015.03.01110.1016/j.ctrv.2015.03.011 ↗
6. 10.3390/ijms22201106110.3390/ijms222011061 ↗
7. 10.1016/j.canlet.2013.09.01810.1016/j.canlet.2013.09.018 ↗
8. 10.1172/JCI13874010.1172/JCI138740 ↗
9. 10.18632/oncotarget.752810.18632/oncotarget.7528 ↗
10. 10.1097/CCO.000000000000081810.1097/CCO.0000000000000818 ↗
11. 10.1667/0033-7587(2000)154[0497:TDOPMT]2.0.CO;210.1667/0033-7587(2000)154[0497:TDOPMT]2.0.CO;2 ↗
12. 10.1016/j.currproblcancer.2015.10.00110.1016/j.currproblcancer.2015.10.001 ↗
13. 10.1002/smtd.20220140110.1002/smtd.202201401 ↗
14. 10.1016/j.semradonc.2014.07.00510.1016/j.semradonc.2014.07.005 ↗
15. 10.1038/ncomms1561810.1038/ncomms15618 ↗
16. 10.1016/j.tcb.2017.06.00110.1016/j.tcb.2017.06.001 ↗
17. 10.1002/adma.20231399110.1002/adma.202313991 ↗
18. 10.1186/s12951-021-01209-410.1186/s12951-021-01209-4 ↗
19. 10.3390/molecules2911243810.3390/molecules29112438 ↗
20. 10.1038/s41467-020-20243-810.1038/s41467-020-20243-8 ↗
21. 10.1016/j.semcancer.2023.11.00610.1016/j.semcancer.2023.11.006 ↗
22. 10.3390/ijms23231467210.3390/ijms232314672 ↗
23. 10.1016/j.ijrobp.2004.03.00510.1016/j.ijrobp.2004.03.005 ↗
24. 10.3390/cells809110510.3390/cells8091105 ↗
25. 10.1038/s41568-020-0246-110.1038/s41568-020-0246-1 ↗
26. 10.1016/j.it.2018.06.00110.1016/j.it.2018.06.001 ↗
27. 10.1016/j.immuni.2018.03.01710.1016/j.immuni.2018.03.017 ↗
28. 10.1038/s41565-021-00962-910.1038/s41565-021-00962-9 ↗
29. 10.1021/acsnano.3c0929310.1021/acsnano.3c09293 ↗
30. 10.1002/advs.20240267810.1002/advs.202402678 ↗
31. 10.1021/acsnano.2c0692610.1021/acsnano.2c06926 ↗
32. 10.1016/j.clon.2021.08.01410.1016/j.clon.2021.08.014 ↗
33. 10.1002/(SICI)1098-2388(199611/12)12:6<407::AID-SSU6>3.0.CO;2-E10.1002/(SICI)1098-2388(199611/12)12:6<407::AID-SSU6>3.0.CO;2-E ↗
34. 10.1016/j.addr.2020.01.00310.1016/j.addr.2020.01.003 ↗
35. 10.1021/nl304478h10.1021/nl304478h ↗
36. 10.1021/nn502146r10.1021/nn502146r ↗
37. 10.1002/adma.20200600310.1002/adma.202006003 ↗
38. 10.1021/ja310501y10.1021/ja310501y ↗
39. 10.1021/jacs.7b0890310.1021/jacs.7b08903 ↗
40. 10.1002/advs.20220484210.1002/advs.202204842 ↗
41. 10.1021/jacs.6b0429910.1021/jacs.6b04299 ↗
42. 10.1002/cam4.680010.1002/cam4.6800 ↗
43. 10.1002/advs.20230410410.1002/advs.202304104 ↗
44. 10.1016/j.biomaterials.2021.12071710.1016/j.biomaterials.2021.120717 ↗
45. 10.1038/s41571-024-00892-010.1038/s41571-024-00892-0 ↗
46. Takeda T. · Gan to Kagaku Ryoho · 2018 · 45 · 1479
47. Sato H. · Gan to Kagaku Ryoho · 2019 · 46 · 845
48. 10.1016/S0022-1759(98)00204-X10.1016/S0022-1759(98)00204-X ↗